Mechanical Circulatory Support in Patients With COVID-19 Presenting With Myocardial Infarction Article

Full Text via DOI: 10.1016/j.amjcard.2022.09.030 Web of Science: 000916876200012

Cited authors

  • Guddeti RR, Sanina C, Jauhar R, Henry TD, Dehghani P, Garberich R, Schmidt CW, Nayak KR, Shavadia JS, Bagai A, Alraies C, Mehra A, Bagur R, Grines C, Singh A, Patel RAG, Htun WW, Ghasemzadeh N, Davidson L, Acharya D, Kabour A, Hafiz AM, Amlani S, Wasserman HS, Smith T, Kapur NK, Garcia S


  • ST-segment elevation myocardial infarction (STEMI) complicating COVID-19 is associ-ated with an increased risk of cardiogenic shock and mortality. However, little is known about the frequency of use and clinical impact of mechanical circulatory support (MCS) in these patients. We sought to define patterns of MCS utilization, patient characteristics, and outcomes in patients with COVID-19 with STEMI. The NACMI (North American COVID-19 Myocardial Infarction) is an ongoing prospective, observational registry of patients with COVID-19 positive (COVID-19+) with STEMI with a contemporary control group of persons under investigation who subsequently tested negative for COVID-19 (COVID-19-). We compared the baseline characteristics and in-hospital outcomes of COVID-19+ and patients with COVID-19- according to the use of MCS. The primary outcome was a composite of in-hospital mortality, stroke, recurrent MI, and repeat unplanned revascularization. A total of 1,379 patients (586 COVID-19+ and 793 COVID-19-) enrolled in the NACMI registry between January 2020 and November 2021 were included in this analysis; overall, MCS use was 12.3% (12.1% [n = 71] COVID-19+/MCS positive [MCS+] vs 12.4% [n = 98] COVID-19-/MCS+). Baseline characteristics were similar between the 2 groups. The use of percutaneous coronary intervention was similar between the groups (84% vs 78%; p = 0.404). Intra-aortic balloon pump was the most fre-quently used MCS device in both groups (53% in COVID-19+/MCS+ and 75% in COVID-19-/MCS+). The primary outcome was significantly higher in COVID-19+/MCS + patients (60% vs 30%; p = 0.001) because of very high in-hospital mortality (59% vs 28%; p = 0.001). In conclusion, patients with COVID-19+ with STEMI requiring MCS have very high in-hospital mortality, likely related to the significantly higher pulmonary involvement compared with patients with COVID-19- with STEMI requiring MCS. (c) 2022 Elsevier Inc. All rights reserved. (Am J Cardiol 2023;187:76-83)

Publication date

  • 2023

Published in

International Standard Serial Number (ISSN)

  • 0002-9149

Number of pages

  • 8

Start page

  • 76

End page

  • 83


  • 187